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Growth hormone and insulin-like growth factor-1 (IGF-1) are essential for the achievement
of normal longitudinal bone growth and bone mass. Preclinical studies using various knock-
out models have shown that both endocrine (mostly liver-derived) IGF-1 and bone-derived
IGF-1 contribute to normal longitudinal skeletal growth and cortical bone size. Since bone
size is an important determinant of bone strength, and hence fracture risk, we evaluated
the predictive role of serum IGF-1 for fracture risk.The population-based Osteoporotic Frac-
tures in Men Sweden cohort recently showed for the ﬁrst time that older men with low
serum IGF-1 levels have an increased fracture risk, especially for the two most important
fracture types, hip and vertebral fractures. This association between serum IGF-1 and inci-
dent fracture risk is partly mediated via bone mineral density. Future studies are required
to identify the mechanisms by which endocrine and local IGF-1 regulate skeletal growth
and bone size. In addition, possible mediators affecting the impact of IGF-1 on fractures in
men remain to be elucidated.
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INTRODUCTION
Insulin-like growth factor-1 (IGF-1) is a key mediator of the
growth-promoting effects of growth hormone (GH). It is pro-
duced in virtually every tissue of the body, including bone, with
the liver being the principal source of IGF-1 in the blood. IGF-1
is considered to be essential for longitudinal bone growth, skele-
tal maturation, and bone mass acquisition during growth and the
maintenance of bone mass in adults (Giustina et al., 2008; Ohlsson
et al., 2009).
Osteoporosis-related fractures constitute an important public
health issue, not only in women but also in men. Besides high
social and economic costs associated with fractures, mortality is
increased in patients with hip and vertebral fractures, even more
so in men than in women (Center et al., 1999b).
In this mini-review, we will shortly summarize the role of IGF-
1 for bone growth and maintenance using animal knockout (KO)
models. In addition, our latest ﬁndings from population-based
cohorts regarding the predictive role of serum IGF-1 for fractures
are discussed.
BOTH SERUM AND LOCALLY PRODUCED IGF-1 CONTRIBUTE
TO LONGITUDINAL BONE GROWTH AND CORTICAL
BONE SIZE
Systemic as well as locally produced IGF-1 can affect the skele-
ton. To investigate the relative contribution of systemic versus
local IGF-1, transgenic mouse models were developed using the
Cre-loxP system. Mouse models with speciﬁc inactivation of the
igf-1 gene in the liver showed an approximately 75% reduc-
tion in serum IGF-1 levels, conﬁrming that hepatic IGF-1 is
the major contributor to circulating IGF-1 levels (Sjögren et al.,
1999; Yakar et al., 1999). Despite these decreases in serum IGF-
1, postnatal body growth was preserved and bone length was
largely unaffected. Serum IGF-1 levels were even more reduced
in KO mouse models of liver-derived IGF-1 combined with acid-
labile subunit and/or total IGF binding protein 3 (removing
endocrine IGF-1). These mice displayed a modest but signiﬁ-
cant reduction in total body length (Yakar et al., 2002, 2009).
When looking on the bone phenotype in more detail using com-
puted tomography and histomorphometry, the liver-speciﬁc IGF-
1 KO mice showed a signiﬁcant reduction in cortical bone mass.
Cortical thickness and periosteal circumference were decreased
(Sjögren et al., 2002; Yakar et al., 2002), which was associ-
ated with reduced bone strength in adult mice (Sjögren et al.,
2002). These models indicate a role for endocrine IGF-1 in
the regulation of normal longitudinal bone growth and cortical
bone size.
The role of local bone-derived IGF-1 was examined in mouse
models with osteoblast- or chondrocyte-speciﬁc inactivation of
IGF-1 (Govoni et al., 2007a,b). These mice displayed reduced
femur length (−7% in the chondrocyte KO and −15% in the
osteoblast KO) while serum IGF-1 levels were unaffected, indi-
cating that IGF-1 from both chondrocytes and osteoblasts partic-
ipates in the regulation of bone growth. Cortical bone was also
affected in these mice, showing reduced bone width and bone
mass in both models (Govoni et al., 2007a,b). Thus, local IGF-1
fromchondrocytes andosteoblasts seems essential for bothnormal
bone length and width.
Taken together, these models indicate that both circulating
(endocrine) IGF-1 and bone-derived IGF-1 are required for nor-
mal longitudinal bone growth and optimal accrual of cortical
bone. Since both sources of IGF-1 have, to some extent, overlap-
ping growth-promoting effects, theymaypartly butnot completely
be redundant for normal longitudinal bone growth (Ohlsson et al.,
2009).
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THE PREDICTIVE ROLE OF SERUM IGF-1 FOR FRACTURE RISK
Patients with IGF deﬁciency as a result of deletion or muta-
tion of the IGF1 gene display osteopenia, indicating a role for
IGF-1 in bone metabolism (Woods et al., 1996; Bonapace et al.,
2003; Walenkamp et al., 2005). Evaluation of the relationship
between serum IGF-1 levels and bone mineral density (BMD)
yielded conﬂicting results, with a positive association being found
in some studies (Barrett-Connor and Goodman-Gruen, 1998;
Janssen et al., 1998; Langlois et al., 1998) whereas no associ-
ation was found in others (Bennett et al., 1984; Center et al.,
1999a). Moreover, the Rancho Bernardo Study (Barrett-Connor
and Goodman-Gruen, 1998) and the Framingham Study (Lan-
glois et al., 1998) found positive associations between serum IGF-1
levels and BMD in women but not in men, whereas the same cor-
relation was found in men but not in women in the Rotterdam
Study (Janssen et al., 1998).
The various experimental mouse models described above sug-
gest that serum IGF-1 levels contribute to bone growth and the
accrual of an optimal cortical bone size. Since the resistance of
bone to bending or torsional forces is related exponentially to
its diameter, the bone size is an important contributor to bone
strength, and ultimately fracture risk (Orwoll, 2003). Therefore,
we assessed the available evidence for a predictive value of serum
IGF-1 levels for risk of fracture.
Several studies reported lower serum IGF-1 levels in women
with prevalent fractures compared with women without fractures
(Sugimoto et al., 1997; Munoz-Torres et al., 2001; Kanazawa et al.,
2007). The only prospective fracture study to date in women by
Garnero et al. (2000) found an association between low base-
line IGF-1 levels and increased risk of fractures. Women with
serum IGF-1 concentrations below the median (212 ng/ml) had
a relative risk of fracture of 3.1 compared with women with
concentrations above the median. Since the study included 435
postmenopausal women of whom only 55 sustained a fracture,
it had limited statistical power and was unable to evaluate the
association between serum IGF-I and fracture type. To determine
the predictive value of serum IGF-1 for fracture risk in men, we
followed older men (n = 2902) participating in the prospective
Osteoporotic Fractures in Men (MrOS) Sweden study for a mean
of 3.3 years (Ohlsson et al., 2011). Low serum IGF-1 levels were
associated with increased risk of all fractures, hip fractures, and
vertebral fractures in these men. The risk of hip and vertebral
fractures increased by 45 and 40% per SD decrease in serum IGF-
1, respectively. Serum levels of IGF-1 below but not above the
median (112 ng/ml) were inversely related to the yearly incidence
of fractures (Figure 1). The highest risk of fractures was seen for
the 25% of the subjects with serum IGF-1 levels below 85 ng/ml.
In addition, the population-attributable risk proportion was 7.5%
for all fractures and 22.9% for hip fractures. In this cohort, low
levels of serum IGF-1 associated not only with increased fracture
risk but also with low BMD. Therefore, adjustment for BMD was
performed which attenuated the predictive role of serum IGF-1
for hip fractures and vertebral fractures, suggesting that at least
part of the association between serum IGF-1 and fracture risk is
mediated via BMD. Neuromuscular function and falls may also
impact on fracture risk independent of BMD. However, our data
FIGURE 1 |Yearly incidence of fracture in relation to serum IGF-1.
Poisson regression models were used to determine the relation between
serum IGF-1 levels and risk of fractures. The quartile limits (25, 50, and
75%) are indicated by vertical lines in the ﬁgure. Reproduced from Ohlsson
et al. (2011) with permission of the American Society for Bone and Mineral
Research.
argue against a mediating role of neuromuscular function in the
association between serum IGF-1 and fracture risk, since this asso-
ciation was not affected by adjustment for grip strength, total body
lean mass, or falls. In conclusion, this well-powered study was the
ﬁrst to show that older men with low serum IGF-1 levels have
an increased risk of fractures, especially for the two most impor-
tant fracture types, hip and vertebral fractures (Ohlsson et al.,
2011).
CONCLUSION
Both systemic and bone-derived IGF-1 play a critical role in nor-
mal longitudinal bone growth, bone development, and cortical
bone mass accrual, as evidenced by various KO mouse mod-
els. Future studies are needed to determine the mechanisms by
which endocrine and local IGF-1 regulate skeletal growth and
bone size. Findings from our MrOS Sweden cohort show that in
older men, serum IGF-1 is a predictor of incident fractures, more
speciﬁcally, of the two most important fractures types, hip and
vertebral fractures, in older men. This relationship between serum
IGF-1 and risk of fracture is partly dependent on BMD. Still, fur-
ther studies are needed to identify other mediators affecting this
association.
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